Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature

被引：43
|
作者：
Wink, Krista C. J. [1 ]
Roelofs, Erik [1 ]
Solberg, Timothy [2 ]
Lin, Liyong [2 ]
Simone, Charles B., II [2 ]
Jakobi, Annika [3 ,4 ,5 ]
Richter, Christian [3 ,4 ,5 ,6 ,7 ]
Lambin, Philippe [1 ]
Troost, Esther G. C. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol,MAASTRO Clin, Maastricht, Netherlands
[2] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[3] Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany
[4] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany
[5] Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany
[6] German Canc Consortium DKTK Dresden, Heidelberg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
来源：
FRONTIERS IN ONCOLOGY | 2014年 / 4卷
关键词：
radiotherapy; NSCLC; photon; proton; C-ion; PSPT; PBS; IMPT;
D O I：
10.3389/fonc.2014.00292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This review article provides a systematic overview of the currently available evidence on the clinical effectiveness of particle therapy for the treatment of non-small cell lung cancer and summarizes findings of in silico comparative planning studies. Furthermore, technical issues and dosimetric uncertainties with respect to thoracic particle therapy are discussed.
引用
收藏
页数：15
相关论文
共 50 条
  • [1] Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?
    Azim, Hatem A., Jr.
    Ganti, Apar Kishor
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 (08) : 630 - 636
  • [2] Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?
    Aggarwal, Charu
    Langer, Corey J.
    [J]. CANCER, 2020, 126 (05) : 931 - 934
  • [3] Minimally Invasive Surgery in Non-Small Cell Lung Cancer: Where Do We Stand?
    Berzenji, Lawek
    Wen, Wen
    Verleden, Stijn
    Claes, Erik
    Yogeswaran, Suresh Krishan
    Lauwers, Patrick
    Van Schil, Paul
    Hendriks, Jeroen M. H.
    [J]. CANCERS, 2023, 15 (17)
  • [4] Particle therapy in lung cancer: Where do we stand?
    Pijls-Johannesmata, Madelon
    Grutters, Janneke P. C.
    Lambin, Philippe
    De Ruysscher, Dirk
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 (03) : 259 - 267
  • [5] Antiangiogenic agents in the management of non-small cell lung cancer Where do we stand now and where are we headed?
    Aggarwal, Charu
    Somaiah, Neeta
    Simon, George R.
    [J]. CANCER BIOLOGY & THERAPY, 2012, 13 (05) : 247 - 263
  • [6] Non-small cell lung cancer and CHART (Continuous Hyperfractionated Accelerated Radiotherapy) - where do we stand?
    Eakin, RL
    Saunders, MI
    [J]. ULSTER MEDICAL JOURNAL, 2000, 69 (02): : 128 - 136
  • [7] Microneedling: Where do we stand now? A systematic review of the literature
    Ramaut, Lisa
    Hoeksema, Henk
    Pirayesh, Ali
    Stillaert, Filip
    Monstrey, Stan
    [J]. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2018, 71 (01): : 1 - 14
  • [8] Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go
    Patel, JD
    Pasche, B
    Argiris, A
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (03) : 175 - 186
  • [9] Oligometastatic non-small cell lung cancer: Where do we go next?
    Malik, Nauman
    Palma, David
    [J]. LUNG CANCER, 2017, 106 : 145 - 147
  • [10] Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro, Alexandre
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (02) : 154 - 164
12345